This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Same Problems In "New" Research On Autism And Vaccines

"New" study from DeStefano et al., rehashes flawed data - says SafeMinds

WASHINGTON, April 8, 2013 /PRNewswire-USNewswire/ -- A new book chapter on statistical methods in Recent Advances in Autism Spectrum Disorders by University of Northern Iowa researchers, DeSoto and Hitlan[1] documents major methodological flaws in the data set said to disprove the link between Thimerosal-preserved vaccines and autism by Price, et al.[2]   More recently DeStefano et al. [3] used the same data set while attempting to disprove a link between the number of vaccines and autism .

"Both researchers tested whether any increased risk of autism was associated with increased exposures via vaccination.  To do so, they must compare different levels of exposure.  They failed to do so when they matched cases to controls on birth-year and HMO.  Birth-year, by itself, defines exposure level and HMOs further ensures similarity guaranteeing cases and controls were nearly identical on the exposure," said lead author Dr. Catherine DeSoto.  "This is a design flaw called overmatching, it forces cases and controls to be artificially similar and renders the results invalid."

The number, type and timing of vaccines US children receive is a function of birth-year. Formulations purchased and administered would be the same within a given HMO.    

"By matching on birth year and HMO, they eliminated the variability right from the start," said Sallie Bernard, President of SafeMinds.  "Here's a perfect example of the cascading impact from problem data analysis. The same statistical flaws in Price's 2010 research resurface in De Stefano's 2013 research."

"Once again, media reported exactly what CDC released last week without critically reviewing the information," said Eric Uram, Executive Director at SafeMinds. 

Prior to approving Price et al. research, an appointed panel reviewed the study methodology raising design concerns.  Ultimately, the Centers for Disease Control and Prevention (CDC) National Immunization Program dismissed them.  In 2010, SafeMinds challenged the  Price et al., article's claims by highlighting flaws related to errors in the design. [4]  "Peer reviewers should reach agreement," concluded Bernard. "With Price, final approval processes were tipped to accept flawed methods."

SafeMinds maintains listings on peer reviewed research performed by independent scientists documenting neural risks associated with thimerosal and vaccination.  Reporters are encouraged to review and then contact the doctors and scientists doing high-quality work on the issues.[5]

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs